FDA Approves Merck Animal Health’s BRAVECTO® QUANTUM, a Year-Long Injectable Flea and Tick Treatment for Dogs
Merck Animal Health, a division of Merck & Co., announced FDA approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension)—a once-yearly injectable treatment for flea and tick prevention in dogs. The product will be available at veterinary clinics across the U.S. starting August 2025.
BRAVECTO QUANTUM was first approved in Australia and New Zealand in 2023, followed by the EU in 2024, and is now authorized in over 50 countries. It is the first and only systemically administered parasiticide that offers 12 months of continuous protection from fleas and major tick species with a single injection.
This product sets a new benchmark in parasite prevention,” said Dr. Christine Royal, VP of Merck Animal Health’s Companion Animal and Equine business. “It gives veterinarians and pet owners an easy, effective way to protect dogs year-round.
The injectable is approved for dogs and puppies 6 months and older, providing:
- 12-month protection against fleas (Ctenocephalides felis), black-legged ticks, American dog ticks, and brown dog ticks
- 8-month protection against lone star ticks (Amblyomma americanum)
Backed by patented fluralaner technology, BRAVECTO QUANTUM addresses the risk of parasite-borne diseases and allergic dermatitis, even in cooler seasons when ticks can remain active. Its once-a-year dosing is designed to improve compliance and reduce the burden on pet owners.
Recognized for its innovation, BRAVECTO QUANTUM has received the 2024 Edison Award and the S&P Global Award for Best New Companion Animal Product.
About BRAVECTO®
Since launching in 2014, BRAVECTO has distributed over 350 million doses worldwide, offering long-lasting flea and tick protection in multiple formulations for dogs and cats.
Safety Information
Common side effects reported in U.S. field studies include lethargy, vomiting, diarrhea, decreased appetite, and elevated liver enzymes. Use with caution in dogs with neurologic disorders. Safety has not been established in breeding, pregnant, or lactating dogs. Fluralaner belongs to the isoxazoline class, which has been associated with neurologic adverse events, including seizures.
Merck Animal Health
Merck Animal Health, known as MSD Animal Health outside the U.S. and Canada, delivers science-driven veterinary pharmaceuticals, vaccines, and tech-enabled health solutions. Operating in over 50 countries and distributing to around 150 markets, the company is committed to improving animal health and welfare globally.
